Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE-Reference-Cited by-同舟云学术

Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE

Published:2024-02-12 Issue:8 Volume:130 Page:1348-1355
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Shen Fei^ORCID,Jiang Guanglong^ORCID,Philips Santosh,Cantor Erica,Gardner Laura,Xue Gloria,Cunningham Geneva,Kassem Nawal,O’Neill Anne,Cameron David,Suter Thomas M.,Miller Kathy D.^ORCID,Sledge George W.,Schneider Bryan P.^ORCID

Funder

Susan G. Komen for the Cure, Komen Wyoming Affiliate

Vera Bradley Foundation for Breast Cancer

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-024-02602-0.pdf

Reference41 articles.

1. Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.

2. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–47.

3. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.

4. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.

5. Miller KD, O’Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, et al. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol. 2018;36:2621–9.